Satisfaction with single maintenance and reliever therapy or as-needed combined inhaled corticosteroid-formoterol in adults with asthma

J Allergy Clin Immunol Pract. 2023 Mar;11(3):952-954.e1. doi: 10.1016/j.jaip.2022.11.024. Epub 2022 Dec 5.

Authors

Anthony F LaCava¹, Patrick K Gleeson², Andrea J Apter²

Affiliations

¹ Section of Allergy and Immunology, Division of Pulmonary, Allergy, and Critical Care Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pa. Electronic address: lacavaa@ccf.org.
² Section of Allergy and Immunology, Division of Pulmonary, Allergy, and Critical Care Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pa.

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural

MeSH terms

Administration, Inhalation
Adrenal Cortex Hormones / therapeutic use
Adult
Anti-Asthmatic Agents* / therapeutic use
Asthma* / drug therapy
Bronchodilator Agents / therapeutic use
Budesonide / therapeutic use
Drug Combinations
Ethanolamines / therapeutic use
Formoterol Fumarate / therapeutic use
Humans
Personal Satisfaction

Substances

Formoterol Fumarate
Bronchodilator Agents
Adrenal Cortex Hormones
Budesonide
Ethanolamines
Drug Combinations
Anti-Asthmatic Agents

Grants and funding